{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03909334","nct_id":"NCT03909334","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03909334. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Osimertinib and Ramucirumab","label":"Arm A (Osimertinib and Ramucirumab)","type":"ACTIVE_COMPARATOR"},{"description":"Osimertinib","label":"Arm B (Osimertinib)","type":"ACTIVE_COMPARATOR"}],"collaborators":["M.D. Anderson Cancer Center","Eli Lilly and Company"],"completion_date":{"date":"2027-01","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer","EGFR Gene Mutation","Advanced Cancer","Metastatic Cancer"],"enrollment":{"count":160,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":["Tagrisso"],"type":"DRUG"},{"name":"Ramucirumab","otherNames":["Cyramza"],"type":"DRUG"}],"last_update":"2026-04-17","lead_sponsor":"Xiuning Le","official_title":"An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"3 years"}],"references":[{"citation":"Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol. 2025 Feb;43(4):403-411. doi: 10.1200/JCO.24.00533. Epub 2024 Oct 8.","pmid":"39378386","type":"DERIVED"}],"start_date":{"date":"2019-07-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT03909334"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03909334"}